| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK.
Correspondence to: Brian J. Lipworth, MD, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland DD1 9SY, UK
Objective: To assess the addition of a leukotriene receptor antagonist and a long-acting ß2-agonist as second-line therapy in asthma.
Design: Placebo-controlled, double-dummy, crossover study.
Setting: Outpatient clinic.
Patients: Twenty patients with persistent asthma not controlled with inhaled corticosteroid therapy.
Interventions: Montelukast, 10 mg once daily, or salmeterol, 50 µg bid, each for 2 weeks with 1-week run-in and washout placebo periods.
Measurements and results: Adenosine monophosphate (AMP) bronchial challenge, blood eosinophil count (EOS), exhaled nitric oxide, and lung function after both placebo periods and after the first and last doses of each active treatment. Patients recorded their domiciliary peak expiratory flow (PEF), asthma symptoms, and rescue bronchodilator requirement (RES) twice daily throughout the study. For the primary end point of the provocative concentration of AMP causing a 20% fall in FEV1, compared to placebo (47.5 ± 13.0 mg/mL), there were significant differences with the first (114.1 ± 36.9 mg/mL) and last (94.2 ± 30.4 mg/mL) doses of montelukast as well as the first (160.1 ± 64.5 mg/mL) but not the last (70.1 ± 23.7 mg/mL) dose of salmeterol. Only montelukast produced significant suppression of the EOS. Neither drug affected exhaled nitric oxide levels. There were significant improvements with the first doses of salmeterol for all parameters of lung function. After 2 weeks of treatment, there were significant improvements with both drugs for RES and morning PEF. There were no significant differences between drugs for any end points except EOS.
Conclusions: Montelukast and salmeterol exhibited significant improvements in asthma control when given as second-line therapy. Montelukast also produced significant effects on AMP challenge and EOS suggesting anti-inflammatory activity.
Key Words: adenosine monophosphate • inhaled corticosteroids • montelukast • nitric oxide • salbutamol • symptoms
This article has been cited by other articles:
|
|
 |
|
  V. Vassiliou and C. S Zipitis Long-acting bronchodilators: time for a re-think. J R Soc Med, August 1, 2006; 99(8): 382 - 383. [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Green, C. E. Brightling, S. McKenna, B. Hargadon, N. Neale, D. Parker, C. Ruse, I. P. Hall, and I. D. Pavord Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Eur. Respir. J., June 1, 2006; 27(6): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Mendes, M. A. Campos, A. Hurtado, and A. Wanner Effect of Montelukast and Fluticasone Propionate on Airway Mucosal Blood Flow in Asthma Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1131 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. C. Lee, C. M. Jackson, K. Haggart, and B. J. Lipworth Repeated Dosing Effects of Mediator Antagonists in Inhaled Corticosteroid-Treated Atopic Asthmatic Patients Chest, April 1, 2004; 125(4): 1372 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Snyder, P. D. Blanc, P. P. Katz, E. H. Yelin, and M. D. Eisner Leukotriene Modifier Use and Asthma Severity: How Is a New Medication Being Used by Adults With Asthma? Arch Intern Med, March 22, 2004; 164(6): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bjermer, H. Bisgaard, J. Bousquet, L. M Fabbri, A. P Greening, T. Haahtela, S. T Holgate, C. Picado, J. Menten, S B. Dass, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial BMJ, October 18, 2003; 327(7420): 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sandrini, I. M. Ferreira, C. Gutierrez, J. R. Jardim, N. Zamel, and K. R. Chapman Effect of Montelukast on Exhaled Nitric Oxide and Nonvolatile Markers of Inflammation in Mild Asthma Chest, October 1, 2003; 124(4): 1334 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.P. Currie, C.M. Jackson, S.A. Ogston, and B.J. Lipworth Airway-stabilizing effect of long-acting {beta}2-agonists as add-on therapy to inhaled corticosteroids QJM, June 1, 2003; 96(6): 435 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R H Green, C E Brightling, I D Pavord, and A J Wardlaw Management of asthma in adults: current therapy and future directions Postgrad. Med. J., May 1, 2003; 79(931): 259 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O'Sullivan, M. Akveld, C. M. Burke, and L. W. Poulter Effect of the Addition of Montelukast to Inhaled Fluticasone Propionate on Airway Inflammation Am. J. Respir. Crit. Care Med., March 1, 2003; 167(5): 745 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Lipworth and C. M. Jackson Bronchodilator Reversibility to Albuterol Predicts Bronchodilator Response to Salmeterol Chest, April 1, 2002; 121(4): 1382 - 1382. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Lipworth and W. J. Calhoun THE STEP 3 DILEMMA FOR MODERATE PERSISTENT ASTHMA Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 1022a - 1023. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
